Abstract
The purpose of this study is to determine whether it is feasible to administer high-dose epirubicin (135 mg m–2) combined with a fixed dose of cisplatin every 2 weeks with G-CSF support in patients with metastatic non-small-cell lung cancer (NSCLC). Subsequently, the efficacy of the recommended dose of this regimen was tested in a phase II study in patients with relapsed NSCLC. In the initial feasibility study at least 6 patients were entered at each of the 4 dose levels tested. A fixed dose of cisplatin 60 mg m–2was given. Epirubicin was administered at 120 mg m–2on dose level 1, 135 mg m–2on dose level 2 and 3 and 135 mg m–2on dose level 4. Patients treated at dose level 3 and 4 received G-CSF support on days 3–12. Cycles were repeated every 3 weeks on the first 3 dose levels and every 2 weeks on the fourth dose level. A total of 27 patients were then treated on dose level 4, which appeared to be feasible in the initial study. In the initial study, a total of 86 courses were administered. Haematological toxicity was the principal side effect. None of the patients encountered dose-limiting toxicity in the first course, which confirmed that epirubicin 135 mg m–2could be combined with cisplatin 60 mg m–2and accelerated by G-CSF support to a 14-day-schedule. In the subsequent phase II study with this schedule, 89 courses were administered. The relative dose intensity of cisplatin and epirubicin was 0.90 and 0.91, respectively. Myelosuppression was frequent with 70% and 63% of patients experiencing WHO grade III or IV leukocytopenia and thrombocytopenia, respectively. 6 cases of febrile neutropenia were observed, with 2 treatment-related deaths. Non-haematological toxicity consisted mainly of nausea and vomiting, which was grade III in 22% of patients. Renal toxicity grade I and II occurred in 37% and 4% of patients, respectively. 55% of these patients had received prior cisplatin-containing chemotherapy. On an intention-to-treat basis 9 partial responses were recorded in 27 patients (33%; 95% confidence interval, 15%–51%). Accelerated cisplatin and high-dose epirubicin with G-CSF support is a feasible and promising regimen in relapsed NSCLC. Myelosuppression limits the use of this regimen in the second-line setting to a selected group of patients with a good performance status. Since the activity of this regimen is encouraging, it is probably best studied in untreated patients. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
ASCO (1997) Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 15: 2996–3018
Crinò L, Scagliotti G and Marangolo M et al (1997) Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 15: 297–303
Feld R, Wierzbicki R and Walde PLD et al (1992) Phase I-II study of high-dose epirubicin in advanced non-small cell lung cancer. J Clin Oncol 10: 297–303
Fossella FV, DeVore R and Kerr Ret al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with non-small cell lung cancer previously treated with platinum-containing chemotherapy. J Clin Oncol 18: 2354–2362
Fountzilas G, Skarlos D and Giannakakis T et al (1994) Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgastrim in advanced breast cancer. Eur J Cancer 30: 965–969
Gridelli C, Airoma G and Incoronato P et al (1992) Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small cell lung cancer. Cancer Chemother Pharmacol 30: 212–214
Huisman C, Smit EF, Giaccone G and Postmus PE (2000) Second-line chemotherapy in relapsing or refractory non-small cell lung cancer patients – a review. J Clin Oncol 18: 3722–3730
Joss RA, Hansen HH and Hansen M et al (1984) Phase II clinical trial of epirubicin in advanced squamous, adeno-and large cell carcinoma of the lung. Eur J Cancer Clin Oncol 20: 495–499
Kalman LA, Kris MG and Gralla RJ et al (1983) Phase II trial of 4’-epidoxorubicin in patients with non-small cell lung cancer. Cancer Treat Rep 67: 591–592
Lalisang RI, Voest EE and Wils JA et al (2000) Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer. Br J Cancer 82: 1914–1919
Lelli G, Farris A and Casadio M et al (1986) 4’-epidoxorubicin and cisdiamminedichloroplatinum in advanced non-small cell bronchogenic carcinoma: a phase II study. J Exp Clin Cancer Res 5: 185–190
Martoni A, Giovanni M and Tomasi L (1984) A phase II clinical trial of 4’-epidoxorubicin in advanced solid tumours. Cancer Chemother Pharmacol 12: 179–182
Martoni A, Melotti B and Guaraldi M et al (1991) Activity of high-dose epirubicin in advanced non-small cell lung cancer. Eur J Cancer 27: 1231–1234
Martoni A, Guaraldi M and Casadio L et al (1992) A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small cell lung cancer. Ann Oncol 3: 864–866
Martoni A, Guaraldi M and Piana E et al (1998) Multicenter randomized clinical trial on high-dose epirubicin plus cisplatinum versus vinorelbine plus cisplatinum in advanced non-small cell lung cancer. Lung Cancer 22: 31–38
Meyers FJ, Cardiff RD and Quadro R et al (1986) Epirubicin in non-oat cell lung cancer-response rates and the importance of immunopathology: a northern California oncology group study. Cancer Treat Rep, (1986). 70: 805–806
Non-small cell lung cancer collaborative group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized trials. BMJ 311: 899–909
Rossel R, Gómez-Codina J and Anton A et al (1994) Escalating high-dose epirubicin plus cisplatin in small cell lung cancer with granulocyte-macrophage colony-stimulating factor use when appropriate. Semin Onc 21, (Suppl 1):48–53
Shepherd FA, Dancey J and Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095–2103
Smit EF, Berendsen HH and Piers DA et al (1992) A phase II study of high dose epirubicin in unresectable non small cell lung cancer. Br J Cancer 65: 405–408
Wils J, Utama I and Sala L et al (1990) Phase II study of high dose epirubicin in non-small cell lung cancer. Eur J Cancer 26: 1140–1141
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Huisman, C., Biesma, B., Postmus, P. et al. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy. Br J Cancer 85, 1456–1461 (2001). https://doi.org/10.1054/bjoc.2001.2013
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2013
Keywords
This article is cited by
-
Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer
Bone Marrow Transplantation (2007)
-
Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease)
British Journal of Cancer (2006)
-
Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study
British Journal of Cancer (2005)